The present invention relates to crystalline forms of N-6-(2-Hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2H-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide, to processes for their preparation, to pharmaceutical compositions comprising them and to their use in the control of disorders.
本发明涉及N-6-(2-羟基
丙烷-2-基)-2-[2-(甲磺基)乙基]-
2H-吲哚-5-基}-6-(三
氟甲基)
吡啶-2-甲酰胺的晶型形式,其制备方法,包含它们的药物组合物以及它们在控制疾病中的用途。